drugset / Trial / NCT03159845
Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies
RandomizedParallel-groupOpen-labelSupportive care
Summary
Patients affected by multiple myeloma undergone autologous stem cell transplantation (SCT) are enrolled at the moment of stem cell collection. They are randomized 1:1 in two groups at the moment of the graft. Patients of the Control group take only standard antimicrobial prophylaxis after SCT; the Sample group takes in addition a daily oral supplementation of Zinc Sulfate (600 mg/die) from day +5 until day +100 after SCT. Laboratory tests are performed on peripheral blood samples.
Timeline
- Start
- 2014-01-01
- Primary completion
- 2019-09-10
- Completion
- 2019-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zinc Sulfate | Unknown | 600 mg | — |
| Background | Acyclovir | Small molecule | 400 mg | — |
| Background | Fluconazole | Small molecule | 200 mg | — |
| Background | Levofloxacin | Small molecule | 500 mg | Oral |